News

ISB Gets $3.4M NIH Extension for Cancer Genomics Cloud

FOR IMMEDIATE RELEASE

ISB Receives $3.4 Million Extension to NIH Contract to Continue Development of ‘Cancer Genomics Cloud’ with Google and CSRA

SEATTLE, Oct. 21, 2016 – Institute for Systems Biology (ISB) has received a $3.4 million, one-year extension to an existing federally-funded contract from the National Cancer Institute (NCI), National Institutes of Health (NIH). This follows the completion of the initial two-year, $6.5 million contract during which ISB developed the ISB-CGC, a cloud-based platform that serves as a large-scale data repository and includes both interactive and programmatic interfaces, as well as the computational infrastructure necessary to carry out cancer genomics research at an unprecedented scale. With the additional funding, the ISB-CGC team, which includes partners at Google, Inc., and CSRA, will be able to extend the platform to include new data sets and new data types, in particular diagnostic images and proteomics data.

ISB-CGC already includes over 1 petabyte (PB) of data from The Cancer Genome Atlas (TCGA) project. The data and tools that the ISB-CGC platform provide, together with the compute power of the Google Cloud, have made TCGA data more accessible and more usable than ever before. The amount of data hosted by ISB-CGC will more than double during the extension year as additional data from the NCI Genomic Data Commons (GDC) is added to the current data set.

The NCI also awarded extensions to the Broad Institute and Seven Bridges Genomics.

FUNDING: This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201400007C

ABOUT INSTITUTE FOR SYSTEMS BIOLOGY: The Institute for Systems Biology is a nonprofit biomedical research organization based in Seattle, Washington. It was founded in 2000 by systems biologist Leroy Hood, immunologist Alan Aderem, and protein chemist Ruedi Aebersold. ISB was established on the belief that the conventional models for exploring and funding breakthrough science have not caught up with the real potential of what is possible today. ISB serves as the ultimate environment where scientific collaboration stretches across disciplines and across academic and industrial organizations, where our researchers have the intellectual freedom to challenge the status quo, and where grand visions for breakthroughs in human health inspire a collective drive to achieve the seemingly impossible. Our core values ensure that we always keep our focus on the big ideas that eventually will have the largest impact on human health. ISB is an affiliate of Providence Health & Services.

Media contact:
Hsiao-Ching Chou
Director of Communications
Institute for Systems Biology
hchou@isbscience.org

Recent Articles

  • Cultivated meat illustration

    How Systems Biology Is Helping Advance the Cultivated Meat Industry

    The quest to create cultivated meat has been a true multidisciplinary puzzle. It’s biology, engineering, physics, bioinformatics, mathematics, computer science, and more. Enter systems biology. ISB and other organizations are toiling to better understand how to create lab-grown meat in a safe, effective manner that can eventually scale up to compete with traditional meat.

  • 2021 Innovator Awards

    Three Collaborative Projects Announced for ISB’s 2021 Innovator Award Program

    ISB has kicked off the fifth year of its Innovator Award Program by announcing three collaborative and cross-disciplinary projects. The program was created in 2017 to support early-career scientists working on high-risk, high-reward innovations, and champions interdisciplinary collaboration for non-faculty ISB researchers.

  • CRI iAtlas

    CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

    CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.